TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Immuron Limited ( (AU:IMC) ).
Immuron Limited’s CEO, Steve Lydeamore, addressed the company’s Annual General Meeting, highlighting the company’s ongoing focus on developing innovative treatments for infectious diseases. The announcement underscores Immuron’s commitment to leveraging its unique platform technology to enhance its market position and deliver value to stakeholders.
More about Immuron Limited
Immuron Limited is an Australian biopharmaceutical company that specializes in developing and commercializing orally delivered targeted polyclonal antibodies for treating infectious diseases. Their proprietary technology utilizes polyclonal immunoglobulins derived from engineered hyper-immune bovine colostrum, which are effective against enteric pathogens and remain active in the human gastrointestinal tract.
Average Trading Volume: 469,123
Technical Sentiment Signal: Strong Sell
Current Market Cap: A$19.45M
Find detailed analytics on IMC stock on TipRanks’ Stock Analysis page.